Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)

NCT02920450

Last updated date
Study Location
UF Health Cancer Center
Gainesville, Florida, 32608, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Signed Institutional Review Board (IRB)-approved informed consent prior to any study-related procedures

- Age of 18 years or older

- Advanced-stage unresectable NSCLC, as confirmed by pathological and/or radiological analysis (subjects will be classified as having advanced disease if they were not eligible for, or had disease progression after, surgical or locoregional therapies)

- Prior chemotherapy will be allowed for other invasive malignancies, provided therapy was completed at least five years before the start of protocol therapy, and participants have recovered from all toxicities of that prior therapy

- Participants may have received prior chemotherapy for NSCLC

- In the Phase II portion, subjects must have disease which lacks PTEN expression by immunohistochemistry, or has known prior activating PI3K or inactivating PTEN gene mutations (mutations will not be assayed for specifically)

- Eastern Cooperative Oncology Group (ECOG) performance status score < 2

- Life expectancy ≥ 12 week

- Participants must have measureable disease by RECIST criteria

- Absolute neutrophil count > 1500 mm3 (individuals with benign ethnic neutropenia may be enrolled if they have no evidence of infectious diathesis, or febrile neutropenia at the time of enrollment)

- Platelet count ≥ 100×109 L

- Hgb ≥ 8.5 g/dL (subjects may receive transfusions to achieve this, in the absence of overt bleeding)

- Total Bilirubin ≤ 2 mg/dL

- aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3 times the upper limit of normal range

- Serum creatinine ≤1.5 times the upper limit of the normal range

- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 6 months after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:

- Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or

- For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.

- Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 6 months following the last dose of study drug

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias or
hypertension.


- Myocardial infarction or unstable angina within 2 months of treatment.


- Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B
(subjects will not be screened for this).


- Active clinically serious infection > CTCAE Grade 2.


- Thrombotic or embolic events such as a cerebrovascular accident including transient
ischemic attacks within the past 6 months.


- Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
study drug.


- Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
study drug.


- Serious non-healing wound, ulcer, or bone fracture.


- Evidence or history of bleeding diathesis or coagulopathy


- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
study drug


- Women or men of childbearing potential who are unwilling or unable to use an
acceptable method to avoid pregnancy for the entire study period and for at least 6
months after the last dose of study drug


- Women who are pregnant or breastfeeding.


- History of any other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of protocol therapy or that might affect the interpretation of
the results of the study or that puts the subject at high risk for treatment
complications, in the opinion of the treating physician.


- Prisoners or subjects who are involuntarily incarcerated.


- Subjects who are compulsorily detained for treatment of either a psychiatric or
physical illness.


- Subjects demonstrating an inability to comply with the study and/or follow-up
procedures.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
  1. Gainesville, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT00300729
  1. Gothenburg,
  2. Jönköping,
  3. Kalmar,
  4. Linköping,
  5. Lund,
  6. Malmö,
  7. Skövde,
  8. Trollhättan,
  9. Uddevalla,
  10. Umeå,
  11. Uppsala,
  12. Ystad,
  13. Örebro,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00555256
  1. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
  1. Boston, Massachusetts
  2. Middletown, New Jersey
  3. Pompton Plains, New Jersey
  4. Commack, New York
  5. Harrison, New York
  6. New York, New York
  7. New York, New York
  8. Uniondale, New York
  9. Houston, Texas
  10. Via Albertoni, Bologna
  11. Via Albertoni, Bologna
  12. Via Massarenti, Bologna
  13. Via Massarenti, Bologna
  14. Via Massarenti, Bologna
  15. Via Palagi, Bologna
  16. Milan, Lombardia
  17. Milan, Lombardia
  18. Milan, Lombardia
  19. Milan, Lombardia
  20. Milan, Lombardia
  21. Milan, Lombardia
  22. Milan, Lombardia
  23. Viale Pansini, Napli
  24. Amsterdam, Noord-holland
  25. Amsterdam,
  26. Groningen,
  27. Groningen,
  28. Cordoba,
  29. Los Angeles, California
  30. Santa Monica, California
  31. Norwich, Connecticut
  32. Norwich, Connecticut
  33. Altamonte Springs, Florida
  34. Bonita Springs, Florida
  35. Bradenton, Florida
  36. Brandon, Florida
  37. Cape Coral, Florida
  38. Clearwater, Florida
  39. Fleming Island, Florida
  40. Fort Myers, Florida
  41. Fort Myers, Florida
  42. Gainesville, Florida
  43. Largo, Florida
  44. Lecanto, Florida
  45. Naples, Florida
  46. New Port Richey, Florida
  47. Ocala, Florida
  48. Orange City, Florida
  49. Orlando, Florida
  50. Port Charlotte, Florida
  51. Saint Petersburg, Florida
  52. Saint Petersburg, Florida
  53. Sarasota, Florida
  54. Sarasota, Florida
  55. Spring Hill, Florida
  56. Tallahassee, Florida
  57. Tallahassee, Florida
  58. Tampa, Florida
  59. Tavares, Florida
  60. The Villages, Florida
  61. Venice, Florida
  62. Winter Park, Florida
  63. Atlanta, Georgia
  64. Atlanta, Georgia
  65. Atlanta, Georgia
  66. Atlanta, Georgia
  67. Johns Creek, Georgia
  68. Chicago, Illinois
  69. Overland Park, Kansas
  70. Baltimore, Maryland
  71. Baltimore, Maryland
  72. Baltimore, Maryland
  73. Baltimore, Maryland
  74. Boston, Massachusetts
  75. Boston, Massachusetts
  76. Boston, Massachusetts
  77. Boston, Massachusetts
  78. Boston, Massachusetts
  79. Boston, Massachusetts
  80. Chelsea, Massachusetts
  81. Stoneham, Massachusetts
  82. Stoneham, Massachusetts
  83. Creve Coeur, Missouri
  84. Independence, Missouri
  85. Kansas City, Missouri
  86. Saint Louis, Missouri
  87. Saint Louis, Missouri
  88. Saint Louis, Missouri
  89. Saint Louis, Missouri
  90. Basking Ridge, New Jersey
  91. Hackensack, New Jersey
  92. Montvale, New Jersey
  93. Bronx, New York
  94. Bronx, New York
  95. Bronx, New York
  96. New York, New York
  97. New York, New York
  98. New York, New York
  99. Durham, North Carolina
  100. Columbus, Ohio
  101. Columbus, Ohio
  102. Columbus, Ohio
  103. Columbus, Ohio
  104. Columbus, Ohio
  105. Columbus, Ohio
  106. Columbus, Ohio
  107. Gahanna, Ohio
  108. Lewis Center, Ohio
  109. Clackamas, Oregon
  110. Newberg, Oregon
  111. Portland, Oregon
  112. Portland, Oregon
  113. Pittsburgh, Pennsylvania
  114. Pittsburgh, Pennsylvania
  115. Pittsburgh, Pennsylvania
  116. Pittsburgh, Pennsylvania
  117. York, Pennsylvania
  118. Chattanooga, Tennessee
  119. Chattanooga, Tennessee
  120. Chattanooga, Tennessee
  121. Cleveland, Tennessee
  122. Dickson, Tennessee
  123. Franklin, Tennessee
  124. Gallatin, Tennessee
  125. Hendersonville, Tennessee
  126. Hermitage, Tennessee
  127. Lebanon, Tennessee
  128. Murfreesboro, Tennessee
  129. Nashville, Tennessee
  130. Nashville, Tennessee
  131. Nashville, Tennessee
  132. Nashville, Tennessee
  133. Shelbyville, Tennessee
  134. Smyrna, Tennessee
  135. Houston, Texas
  136. Houston, Texas
  137. Kingwood, Texas
  138. Shenandoah, Texas
  139. The Woodlands, Texas
  140. Seattle, Washington
  141. Faenza, Emilia-romagna
  142. Lugo, Emilia-romagna
  143. Ravenna, Emilia-romagna
  144. Ravenna, Emilia-romagna
  145. Rimini, Emilia-romagna
  146. Roma, Lazio
  147. Milano, Lombardia
  148. Napoli, Naples
  149. Cattolica, Rimini
  150. Orbassano, Torino
  151. Orbassano, Torino
  152. Orbassano, Torino
  153. Orbassano, Torino
  154. Orbassano, Torino
  155. Orbassano, Torino
  156. Orbassano, Torino
  157. Milano,
  158. Napoli,
  159. Torino,
  160. Goyang-si, Gyeonggido
  161. Jeonnam,
  162. Seoul,
  163. Seoul,
  164. Seoul,
  165. Amsterdam, Noord-holland
  166. Majadahonda, Madrid
  167. Malaga, Málaga
  168. Barcelona,
  169. Barcelona,
  170. Barcelona,
  171. Barcelona,
  172. Barcelona,
  173. Cordoba,
  174. Cordoba,
  175. Esplugues de Llobregat,
  176. Hospitalet de Llobregat,
  177. L'Hospitalet,
  178. Madrid,
  179. Madrid,
  180. Malaga,
  181. Sevilla,
  182. Sevilla,
  183. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
Official Title  ICMJE A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung
Brief Summary The purpose of this research study is to determine if the study drug, Gedatolisib (PF-05212384), given in combination with paclitaxel and carboplatin will work against unresectable non-small cell lung cancer.
Detailed Description

Approximately 70% of patients with unresectable non-small cell lung cancer (NSCLC) who receive and progress through frontline chemotherapy will be eligible for second line treatments. Any of the agents which are available for frontline therapy can be used in the salvage setting, though only erlotinib, docetaxel, and pemetrexed (in non-squamous cell carcinoma) are FDA-approved in the salvage setting based upon their demonstrated survival benefit in randomized phase III trials. All three appear to be roughly equivalent in terms of clinical benefit, which is admittedly modest, with response rates <10%, clinical benefit rates of approximately 50%, and overall survivals of approximately 6 months. Still, a substantial number of patients may not benefit from the agents in the salvage treatment setting, thus it is critical to identify those patients who stand to benefit the most.

The study will consist of two phases, Ib and II. The phase Ib portion will study dose escalations in separate 3+3 cohorts using escalating doses of PF-05212384. The phase II portion will consist of a two stage Simon design. The doses for paclitaxel (200 mg/m2, Q21 days) and carboplatin (AUC=6, Q21 days) do not adjust as part of the study design. The dose of PF-05212384 will be determined during the Phase Ib portion.

The primary endpoint of the phase Ib portion of this protocol is to determine a tolerable phase II dose of PF-05212384 in combination with paclitaxel and carboplatin. The primary endpoint of the phase II portion of this study is to determine the objective response rate of disease to the administration of PF-05212384 in combination with paclitaxel and carboplatin. A secondary endpoint of this study will be progression-free survival following PF-05212384 therapy.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non-Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Gedatolisib

    During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.

    Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg

    Other Name: PF-05212384
  • Drug: Paclitaxel
    Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
    Other Names:
    • Taxol®
    • NSC-673089
  • Drug: Carboplatin
    The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
    Other Names:
    • CBDCA
    • NSC-241240
Study Arms  ICMJE
  • Experimental: Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])
    Interventions:
    • Drug: Gedatolisib
    • Drug: Paclitaxel
    • Drug: Carboplatin
  • Experimental: Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])
    Interventions:
    • Drug: Gedatolisib
    • Drug: Paclitaxel
    • Drug: Carboplatin
  • Experimental: Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])
    Interventions:
    • Drug: Gedatolisib
    • Drug: Paclitaxel
    • Drug: Carboplatin
  • Experimental: Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)
    Interventions:
    • Drug: Gedatolisib
    • Drug: Paclitaxel
    • Drug: Carboplatin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 9, 2019)
3
Original Estimated Enrollment  ICMJE
 (submitted: September 28, 2016)
41
Actual Study Completion Date  ICMJE April 4, 2019
Actual Primary Completion Date January 2, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed Institutional Review Board (IRB)-approved informed consent prior to any study-related procedures
  • Age of 18 years or older
  • Advanced-stage unresectable NSCLC, as confirmed by pathological and/or radiological analysis (subjects will be classified as having advanced disease if they were not eligible for, or had disease progression after, surgical or locoregional therapies)
  • Prior chemotherapy will be allowed for other invasive malignancies, provided therapy was completed at least five years before the start of protocol therapy, and participants have recovered from all toxicities of that prior therapy
  • Participants may have received prior chemotherapy for NSCLC
  • In the Phase II portion, subjects must have disease which lacks PTEN expression by immunohistochemistry, or has known prior activating PI3K or inactivating PTEN gene mutations (mutations will not be assayed for specifically)
  • Eastern Cooperative Oncology Group (ECOG) performance status score < 2
  • Life expectancy ? 12 week
  • Participants must have measureable disease by RECIST criteria
  • Absolute neutrophil count > 1500 mm3 (individuals with benign ethnic neutropenia may be enrolled if they have no evidence of infectious diathesis, or febrile neutropenia at the time of enrollment)
  • Platelet count ? 100×109 L
  • Hgb ? 8.5 g/dL (subjects may receive transfusions to achieve this, in the absence of overt bleeding)
  • Total Bilirubin ? 2 mg/dL
  • aspartate aminotransferase/alanine aminotransferase (AST/ALT) ? 3 times the upper limit of normal range
  • Serum creatinine ?1.5 times the upper limit of the normal range
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 6 months after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:
  • Amenorrhea that has lasted for ? 12 consecutive months without another cause, or
  • For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.
  • Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 6 months following the last dose of study drug

Exclusion Criteria:

  • Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias or hypertension.
  • Myocardial infarction or unstable angina within 2 months of treatment.
  • Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B (subjects will not be screened for this).
  • Active clinically serious infection > CTCAE Grade 2.
  • Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
  • Pulmonary hemorrhage/bleeding event ? CTCAE Grade 2 within 4 weeks of first dose of study drug.
  • Any other hemorrhage/bleeding event ? CTCAE Grade 3 within 4 weeks of first dose of study drug.
  • Serious non-healing wound, ulcer, or bone fracture.
  • Evidence or history of bleeding diathesis or coagulopathy
  • Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
  • Women or men of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 6 months after the last dose of study drug
  • Women who are pregnant or breastfeeding.
  • History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
  • Prisoners or subjects who are involuntarily incarcerated.
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
  • Subjects demonstrating an inability to comply with the study and/or follow-up procedures.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02920450
Other Study ID Numbers  ICMJE IRB201601181 -A
WI211924 ( Other Identifier: Pfizer Inc. )
UF-STO-LUNG-002 ( Other Identifier: University of Florida )
OCR15075 ( Other Identifier: University of Florida )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party University of Florida
Study Sponsor  ICMJE University of Florida
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Dennie Jones, MDUniversity of Florida
PRS Account University of Florida
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP